Diabetes and heart failure (HF) are closely linked, with one causing a worse prognosis in the other. The majority of anti-hyperglycaemic agents primarily reduce risk of ischaemic microvascular events without targeting the mechanisms involved for diabetes cardiomyopathy and HF. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a novel class of glucose-lowering agents that have consistently reduced HF hospitalisations, unlike other agents. The authors discuss the current evidence and highlight possible future directions for the role of SGLT2 inhibitors in HF prevention. Table 4: Effects of SGLT2 Inhibitors on Renal Outcomes Study AKI, RR [95% CI] ESRD, RR [95% CI] Substantial Loss of Kidney Function, ESRD or Death Due to Renal Cause, RR [95% CI] CREDENCE 27 0.85 [0.64-1.13] 0.68 [0.54-0.86] 0.66 [0.53-0.81] EMPA-REG OUTCOME 9 0.76 [0.62-0.93] 0.60 [0.18-1.98] 0.54 [0.40-0.75] CANVAS 11 0.66 [0.39-1.11] 0.77 [0.30-1.97] 0.53 [0.33-0.84] DECLARE-TIMI 58 12 0.69 [0.55-0.87] 0.31 [0.13-0.79] 0.53 [0.43-0.66] AKI = acute kidney injury; ESRD = end-stage renal disease; SGLT2 = sodium-glucose cotransporter-2.
In 2008, the European Medicines Agency and US Food and Drug Administration (FDA) issued industry guidance stating that all future novel glucose-lowering agent trials must undergo routine cardiovascular risk evaluation either before approval or as a postmarketing commitment. 1 This mandated that all cardiovascular endpoint committees prospectively adjudicate all major adverse cardiovascular events, including cardiovascular death, non-fatal MI and stroke, occurring across Phase II and III diabetes trials. However, the statement did not specifically mention heart failure (HF) as an endpoint.
HF is the second most common cardiovascular presentation of diabetes after peripheral arterial disease. 2 In people with diabetes, mortality from HF constitutes a large proportion of overall mortality. Moreover, approximately 40% of hospitalised HF patients have concomitant diabetes, a trend that is expected to increase even further. [3] [4] [5] Both diabetes and HF are closely linked, with one causing a worse prognosis in the other. The majority of anti-hyperglycaemic agents primarily reduce the risk of ischaemic microvascular events without targeting the mechanisms involved for diabetes cardiomyopathy and HF.
Some glucose-lowering agents, such as thiazolidinediones and saxigliptin, have been linked to increased risk of incident HF and HF hospitalisations. 6, 7 Other drugs, such as liraglutide, have shown overall cardiovascular benefit without specifically improving outcomes in established HF patients. 8 However, unlike other anti-hyperglycaemics, sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a novel class of glucose-lowering agents that have consistently reduced HF hospitalisations. [9] [10] [11] [12] [13] [14] [15] This class of medication works by selectively inhibiting SGLT2, thus causing decreased renal absorption of glucose.
Multiple studies have shown that SGLT2 inhibitors are associated with weight loss and blood pressure reduction in addition to glycaemic control. 16 In this article, we discuss the current evidence and highlight the future direction for SGLT2 inhibitors in HF prevention.
Evidence from Randomised Clinical Trial and Observational Data
There are three completed cardiovascular safety trials for SGLT2 inhibitors: EMPAgliflozin cardiovascular outcome event trial in type 2 diabetes -Removing Excess Glucose (EMPA-REG OUTCOME),
CANagliflozin cardioVascular Assessment Study (CANVAS) and
Dapagliflozin Effect on CardiovascuLAR Events -Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58). 9, 11, 12 In EMPA-REG OUTCOME, 7,020 people with diabetes and established cardiovascular disease were randomised to empagliflozin or placebo. 9 The primary endpoint of the trial -major adverse cardiovascular events p<0.001). Consistent benefit in HF hospitalisation was observed in all subgroups including age, race, estimated glomerular filtration rate (eGFR) and baseline medications for HF. Empagliflozin was also beneficial across a spectrum of HF patients. 17 The results of these trials led to empagliflozin being approved by the FDA in 2016 for the prevention of major adverse cardiovascular events in people with 18 However, no specific recommendation was given for HF prevention, as HF was not one of the primary endpoints.
In the CANVAS trial,10,142 people with diabetes and high cardiovascular risk were randomised to canagliflozin or placebo. 11 The primary endpoint was major adverse cardiovascular events, which was significantly reduced in the canagliflozin group (HR 0.86; 95% CI [0.75-0.97];
p<0.001 for non-inferiority; p=0.02 for superiority). Canagliflozin was also associated with a significant reduction in the risk of HF hospitalisation (5.5 versus 8.7 per 1,000 patient-years; HR 0.67; 95% CI [0.52-0.87]).
Subgroup analyses showed that patients with baseline HF derived a greater benefit in terms of cardiovascular death and HF hospitalisations.
In the recent DECLARE-TIMI 58 trial, which evaluated 17,160 patients, dapagliflozin also significantly reduced the risk of HF hospitalisation (6.2 versus 8.5 per 1,000 patient years; HR 0.73; 95% CI [0.61-0.88]). 12 Approximately 4% of patients had HF with reduced ejection fraction The DECLARE-TIMI 58 trial was unique compared with the previous two trials because it enrolled more patients without known atherosclerotic cardiovascular disease (n=10,186) and was the first trial to include HF hospitalisation as the co-primary endpoint. The baseline HF rate in all three trials was <15%. Table 1 shows baseline characteristics of the three SGLT2 inhibitor trials, and Table 2 shows detailed HF outcomes.
These clinical trial data are further supported by the real-world evidence from observational studies. [13] [14] [15] The Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors study (CVD-REAL), comprising more than 300,000 newly diagnosed diabetes patients, compared those who were initiated on SGLT2 inhibitors with those receiving any other glucose-lowering therapy. SGLT2 inhibitors led to an almost 40% relative reduction in HF hospitalisation compared with other therapies. 13 A consistent benefit was seen in mortality and HF hospitalisation across the spectrum of patients, including those with or without HF at baseline. Moreover, a network meta-analysis suggested that SGLT2 inhibitors have 99.6% probability of being the most effective anti-hyperglycaemic agent for reducing the risk of HF hospitalisation. 19 Table 3 shows the main HF outcomes from the realworld observational data of SGLT2 inhibitors.
Mechanism for Benefit
The cardioprotective effects offered by SGLT2 inhibitors cannot be solely attributed to glycaemic control. Several mechanisms for the beneficial effect of SGLT2 inhibitors in regards to HF have been proposed and are highlighted in Figure 1 .
First, SGLT2 inhibitors have a direct effect on cardiac metabolism by increasing hepatic neogenesis of ketone bodies, which serve as the alternate fuel for a hypertrophied and failing heart. 20 Second, SGLT2 inhibitors are believed to inhibit myocardial and renal sodium-hydrogen exchanger 3, leading to modification of intracellular calcium and thus prevention of HF-associated remodelling. 21 Third, improvement in renal function and interstitial volume regulation by SGLT2 inhibitors may also contribute to improvement in HF risk. 22 Finally, SGLT2 inhibitors cause osmotic diuresis through glycosuria and natriuresis, which may help in optimising loading conditions of the myocardium. SGLT2 inhibitors have also been shown to significantly reduce blood pressure and biomarkers of arterial stiffness, which can lead to better oxygen consumption of the heart. [20] [21] [22] These mechanisms -aside from glycaemic control -also suggest a role for the use of SGLT2 inhibitors solely for HF prevention, regardless of diabetes status.
Effect on Subgroups
In the early SGLT2 inhibitor trials, the benefit for major adverse cardiovascular events seemed to be higher in patients with established atherosclerotic cardiovascular disease, although formal heterogeneity 
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was not shown. This led to the American and European guidelines recommending the use of SGLT2 inhibitors in people with diabetes and atherosclerotic cardiovascular disease. 23, 24 However, a recent meta-analysis including data from EMPA-REG OUTCOME, the CANVAS Program and DECLARE-TIMI 58 showed that SGLT2 inhibitors reduce HF hospitalisations regardless of the presence of HF or atherosclerotic cardiovascular disease at baseline. 25 There was an approximately 30% relative risk reduction for HF hospitalisation in both the subgroups.
Interestingly, the benefit for major adverse cardiovascular events was only limited to patients with baseline atherosclerotic cardiovascular disease. Thus, data suggest that SGLT2 inhibitors are especially beneficial for HF over a broad spectrum of patients with diabetes.
Studies have also demonstrated that the beneficial effect of SGLT2 inhibitors on HF hospitalisation is similar in males and females. 26 On pooling results from all the four studies, SGLT2 inhibitors were shown to decrease the risk of dialysis, transplantation or mortality due to renal disease by approximately one-third. 28 SGLT2 inhibitors were also shown to decrease the risk of acute kidney injury by 25%. Results from each of the individual studies on various renal endpoints are shown in Table 4 . Moreover, significant evidence of benefit was apparent for all eGFR subgroups, , including for patients with a baseline eGFR <45 ml/min/1.73 m 2 . 28 An eGFR rate of ≥30 ml/ min/1.73 m 2 was an inclusion criterion for all four studies apart from DECLARE-TIMI 58, in which a creatinine clearance of ≥60 ml/min was used. Similar to the HF effect, the reno-protective effect was robust in both patients with and without atherosclerotic cardiovascular disease. It is known that patients with lower eGFR are at higher risk for HF hospitalisation, and thus SGLT2 inhibitors conferring reno-protection and natriuresis could be the main contributing mechanism for HF prevention. 29, 30 
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Current Position and Future Direction
In the current guidelines published by the American Diabetes 
